Artículos publicados

Artículos publicados Encontrados 1 registros  La búsqueda tardó 0.01 segundos. 
1.
13 p, 1.9 MB Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features : integrated analysis of two phase 3 studies / Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ; Demirkan, Fatih (Dokuz Eylul University) ; Bairey, Osnat (Rabin Medical Center) ; Moreno, Carolina (Institut d'Investigació Biomèdica Sant Pau) ; Simpson, D. (BeiGene) ; Munir, Talha (Department of Haematology. St. James's Hospital) ; Stevens, D.A. (Norton Cancer Institute) ; Dai, S. (Pharmacyclics LLC. an AbbVie Company) ; Cheung, Leo W. K (Pharmacyclics LLC. an AbbVie Company) ; Kwei, Kevin (Pharmacyclics LLC. an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC. an AbbVie Company) ; Hsu, E. (Pharmacyclics LLC. an AbbVie Company) ; Kipps, Thomas J (University of California San Diego. Moores Cancer Center) ; Tedeschi, A. (ASST Grande Ospedale Metropolitano Niguarda)
Genomic abnormalities, including del(17p)/TP53 mutation, del(11q), unmutated IGHV, and mutations in BIRC3, NOTCH1, SF3B1, and XPO1 predict poor outcomes with chemoimmunotherapy in chronic lymphocytic leukemia. [...]
2022 - 10.1080/10428194.2021.2020779
Leukemia and Lymphoma, Vol. 63 Núm. 6 (2022) , p. 1375-1386  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.